Window of opportunity trials in head and neck cancer

Janice L. Farlow(Indiana University Health), Matthew E. Spector(Michigan Medicine), Andrew C. Birkeland(University of California, Davis), Paul Swiecicki(University of Michigan), J. Chad Brenner(University of Michigan)
Journal of Cancer Metastasis and Treatment
March 18, 2019
10.20517/2394-4722.2018.100
Cited by 12

Related Papers

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
|Proceedings of the National Academy of Sciences|2013|833
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
|Journal of the National Comprehensive Cancer Network|2022|532
Management of Salivary Gland Malignancy: ASCO Guideline
|Journal of Clinical Oncology|2021|401
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
|The Lancet Oncology|2021|257
Lessons Learned from Whole Exome Sequencing in Multiplex Families Affected by a Complex Genetic Disorder, Intracranial Aneurysm
|PLoS ONE|2015|141